From the European LeukemiaNet, Gene Expression Profiling Working Group; MLL Munich Leukemia Laboratory, Munich; Department of Hematology and Oncology, University Hospital Benjamin Franklin, Charité, Berlin, Germany; Laboratorio di Ematologia e Oncologia Pediatrica, Università di Padova, Padova; Division of Hematology, "Sapienza" University, Rome, Italy; Centre Hospitalier Universitaire Montpellier, Hôpital St Eloi, Institut de Recherche en Biothérapie, Montpellier, France; Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Salamanca, Spain; Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom; National University of Singapore, Republic of Singapore; Roche Molecular Systems, Pleasanton; Moores Cancer Center, University of California, San Diego, CA; Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; and Departments of Pediatrics and Pathology, Laboratory Corporation of America, Research Triangle Park, NC.

Submitted April 4, 2009; accepted October 26, 2009; published online ahead of print at www.jco.org on April 20, 2010.

Study supplies, instruments, and sample preparation and microarray technology training courses were provided by Roche Molecular Systems, Pleasanton, CA, as part of the AmpliChip Leukemia Research Program, a collaborative effort with the European LeukemiaNet, addressing gene expression signatures in leukemia. This study was also supported in part by Associazione Italiana per la Ricerca sul Cancro (Milan, Italy), Ministero dell'Università e della Ricerca, Fondo per gli Investimenti della Ricerca di Base, COFIN, and PRIN (Rome, Italy).

Both T.H. and A.K. contributed equally to this work.

Presented in part as oral presentation at the 50th Annual Meeting of the American Society of Hematology, December 6-9, 2008, San Francisco, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Torsten Haferlach, MD, MLL Münchner Leukämie Labor GmbH, Max-Lebsche-Platz 31, 81377 München, Germany; e-mail: torsten.haferlach@ml-online.com.

© 2010 by American Society of Clinical Oncology

0732-183X/10/2815-2529/\$20.00

DOI: 10.1200/JCO.2009.23.4732

Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

Torsten Haferlach, Alexander Kohlmann, Lothar Wiczorek, Giuseppe Basso, Geertruy Te Kronnie, Marie-Christine Béné, John De Vos, Jesus M. Hernández, Wolf-Karsten Hofmann, Ken I. Mills, Amanda Gilkes, Sabina Chiaretti, Sheila A. Shurtleff, Thomas J. Kipps, Laura Z. Rassenti, Allen E. Yeoh, Peter R. Papenhausen, Wei-min Liu, P. Mickey Williams, and Robin Foà

A B S T R A C T

Purpose

The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid malignancies.

Methods

The investigation was performed in 11 laboratories across three continents and included 3,334 patients. An exploratory retrospective stage I study was designed for biomarker discovery and generated whole-genome expression profiles from 2,143 patients with leukemias and myelodysplastic syndromes. The gene expression profiling-based diagnostic accuracy was further validated in a prospective second study stage of an independent cohort of 1,191 patients.

Results

On the basis of 2,096 samples, the stage I study achieved 92.2% classification accuracy for all 18 distinct classes investigated (median specificity of 99.7%). In a second cohort of 1,152 prospectively collected patients, a classification scheme reached 95.6% median sensitivity and 99.8% median specificity for 14 standard subtypes of acute leukemia (eight acute lymphoblastic leukemia and six acute myeloid leukemia classes, $n = 693$). In 29 (57%) of 51 discrepant cases, the microarray results had outperformed routine diagnostic methods.

Conclusion

Gene expression profiling is a robust technology for the diagnosis of hematologic malignancies with high accuracy. It may complement current diagnostic algorithms and could offer a reliable platform for patients who lack access to today's state-of-the-art diagnostic work-up. Our comprehensive gene expression data set will be submitted to the public domain to foster research focusing on the molecular understanding of leukemias.

J Clin Oncol 28:2529-2537. © 2010 by American Society of Clinical Oncology

INTRODUCTION

Microarray studies have identified gene expression signatures associated with distinct clinical subtypes of leukemia.¹ In studies of both pediatric and adult acute lymphoblastic leukemia (ALL), patients can be classified according to specific gene expression profiles.²⁻¹⁰ Characteristic signatures, for example, those identified in acute myeloid leukemia (AML) subtypes with t(15;17), t(8;21), inv(16), or t(11q23)/*MLL*, have been confirmed not only with different DNA oligonucleotide microarray designs,^{11,12} but also by using a principally different microarray technology.¹³ Furthermore, gene expression analyses of

nearly 1,000 patients led to the discovery of distinct expression signatures, not only specific among adult acute and chronic leukemia subtypes, but also in comparison to nonleukemia and healthy bone marrow specimens.¹⁴

Because microarray assays can analyze the expression of multiple genes in parallel, they have been proposed as a robust test method for diagnostic usage in a clinical laboratory. However, published data in this area have been derived from relatively small, single-center studies involving archival samples. Here, we report results from 3,334 patients who were analyzed as part of an international study group formed around the European LeukemiaNet

(ELN) in 11 laboratories across three continents (seven from the ELN, three from the United States, and one in Singapore). The collaborative Microarray Innovations in Leukemia (MILE) study program was designed to assess the clinical accuracy of gene expression profiles (compared with current routine diagnostic work-up) of 16 acute and chronic leukemia subclasses, myelodysplastic syndromes (MDSs), and a so-called “none of the target classes” control group that included nonmalignant disorders and normal bone marrow.

METHODS

Study Design

There were two stages in the MILE research study: a retrospective biomarker discovery phase (stage I) using commercially available whole-genome microarrays (HG-U133 Plus 2.0; Affymetrix, Santa Clara, CA) and an independent validation phase (stage II) that was performed in a prospective manner using a newly designed custom chip (AmpliChip Leukemia; Roche Molecular Systems, Pleasanton, CA). Before each stage of the study, designated laboratory operators at each site were trained on the corresponding sample preparation protocol and had demonstrated proficiency in the technology.¹⁵ The individual steps of the sample preparation workflow are available online. All samples in this study were obtained from untreated patients at the time of diagnosis. Cells used for microarray analysis were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. The study design adhered to the tenets of the Declaration of Helsinki and was approved by the ethics committees of the participating institutions before its initiation. The sponsor collected the anonymized patient data and performed the final statistical analysis. All authors had full access to both the primary local microarray data and the final analysis.

Microarray Data Preprocessing and Exploratory Analyses

Data preprocessing included a summarization and quantile normalization step to generate probe set level signal intensities for each microarray

experiment and was performed as previously described.¹⁶ Data visualization and exploratory analyses were performed with Partek Genomics Suite software version 6.3 (Partek, St Louis, MO) and R software version 2.5.1 (<http://www.r-project.org>), including the Affy, MADE4, and Heatplus packages.¹⁷ A margin tree graph was generated following a method previously established in the use of high-dimensional classification of cancer microarray data.¹⁸ The margin tree is learned in an unbiased manner and emerges naturally in a mathematical procedure. All microarray raw data were deposited in National Center for Biotechnology Information's Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>) under series accession number GSE13204.¹⁹

Custom Chip Design

The AmpliChip Leukemia research microarray was specifically customized for the classification of leukemias.²⁰ The chip contained 1,480 distinct probe sets with 11- μ m feature size. The source of the probe set design was based on the commercially available Affymetrix HG-U133 Plus 2.0 microarray. One thousand four hundred fifty-seven probe sets were used for generating normalized signal intensities of disease-related genes, and 23 probe sets interrogated control sequences and housekeeping genes. Three hundred ninety-eight probe sets were tiled in triplets to increase the robustness of the algorithm performance.

Algorithm Training for Classification Analysis

For multiclass classification, an all-pairwise approach was performed using trimmed mean of differences between perfect match and mismatch intensities with quantile normalization (DQN) signals.¹⁶ For 18 classes, there were 153 distinct class pairs. For every class pair, a linear binary classifier was formed with support vector machines.^{21,22} For this classifier, n was the number of used probe sets. The classifier for class pair (i, j) ($i < j$) consisted of $(n + 1)$ coefficients, $w[0; i, j]$, $w[1; i, j]$, ..., $w[n; i, j]$. Normalized expression signals were denoted by $x[1], \dots, x[n]$. The decision function for class pair (i, j) was $f(x; i, j) = w[0; i, j] + w[1; i, j] * x[1] + \dots + w[n; i, j] * x[n]$. If $f(x; i, j) > 0$, a vote was added to class i ; if $f(x; i, j) < 0$, a vote was added to class j . If $f(x; i, j) = 0$, 0.5 votes were added to class i , and 0.5 votes were added to class j . This process was repeated for all class pairs to obtain the votes for all classes. If there was a unique

Table 1. Overview of Stage I Samples

Class	Diagnosis	Study Center (No. of samples)											Total No. of Samples
		1	2	3	4	5	6	7	8	9	10	11	
C1	Mature B-ALL with t(8;14)	2				2	2	5		1		1	13
C2	Pro-B-ALL with t(11q23)/ <i>MLL</i>	6			12	10	1	33	5	1		2	70
C3	c-ALL/pre-B-ALL with t(9;22)	27			10	15	7	8	39	4		12	122
C4	T-ALL	42	1		19	17	4	38	44			9	174
C5	ALL with t(12;21)				16			23		1		18	58
C6	ALL with t(1;19)	5			11	2		9	3	1		5	36
C7	ALL with hyperdiploid karyotype			1	14	2		14	2			7	40
C8	c-ALL/pre-B-ALL without t(9;22)	50			29	28	2	59	42	3		24	237
C9	AML with t(8;21)		7		1	2	13	5		1		11	40
C10	AML with t(15;17)		2	2			8	5	4	3		13	37
C11	AML with inv(16)/t(16;16)		6		4	3	4	6	3	2			28
C12	AML with t(11q23)/ <i>MLL</i>		4		4	5	6	17	1			1	38
C13	AML with normal karyotype + other abnormalities	2	60	1	12	63	117	19	9	41		27	351
C14	AML complex aberrant karyotype		4	3		2	28	2	1	6		2	48
C15	CLL		15	35		41	81		45	32	199		448
C16	CML			5			44			15		12	76
C17	MDS	28	71	3	1		56			44		3	206
C18	Non-leukemia and healthy bone marrow	19	19				17			16		3	74
Total													2,096

NOTE. Two thousand ninety-six high-quality analyses were performed by 11 different study centers from seven countries across three continents. Eighteen diagnostic gold standard categories are given by their class subtype labels of C1 to C18 and are listed for each participating laboratory (laboratories 1 to 11).

Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; *MLL*, myeloid/lymphoid or mixed-lineage leukemia; pre, precursor; c-ALL, childhood acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome.

Fig 1. Supervised hierarchical clustering. The exploratory whole-genome clustering analysis was performed for all classes (C1 to C18 in ascending order) including 2,096 samples from stage I. For every class pair, the top 100 differentially expressed probes sets with the largest absolute values of *t* statistic were selected. The union of these sets contained 3,556 probe sets used in the clustering.

class with the maximal vote, the call was this particular class. If there was a tie of two or more classes with the maximal vote, an indeterminable call was assigned. The step of probe set selection was included in every cross-validation run and was performed to select the top 100 differentially expressed probe sets with the maximal absolute values of *t* statistic for every class pair. Subsequently, the union of the selected probe sets of all class pairs was used for every binary classifier.

RESULTS

Marker Discovery Phase Using Whole-Genome Microarrays

During stage I of the study, 2,143 whole-genome microarray analyses were performed. Each center had previously diagnosed the samples as part of their daily routine diagnostic work-up, using their local gold standard diagnostic methods, including cytomorphology, immunophenotyping, cytogenetics, and other molecular genetic tests. Each specimen then was assigned based on these previous diagnostic test reports to one of the 18 MILE study categories (C1 to C18) for microarray analysis. Seventeen classes had been selected as representing standard subclasses of acute and chronic leukemias, as well as MDS. Class 18 included healthy bone marrow specimens and nonleukemia conditions, such as megaloblastic anemia, hemolysis, iron deficiency, or idiopathic thrombocytopenic purpura, and was considered to be none of the target classes.

Despite strict quality criteria, 47 samples (2.2%) had to be excluded as a result of low technical quality of the gene expression profiles. The remaining 2,096 samples are listed in Table 1. The samples were not equally distributed among the participating laboratories but were variably contributed depending on each center's expertise (eg, center 10 included chronic lymphocytic leukemia [CLL] specimens and center 7 analyzed cases of pediatric leukemias). Consistent

with the actual incidence of the respective categories, lower sample numbers were submitted for certain uncommon subtypes, including mature B-cell ALL with t(8;14) (C1) and AML with inv(16)/t(16;16) (C11). All other classes comprised more than 30 samples each (range, 36 to 448 samples).

Several approaches were selected to perform exploratory data analyses. First, supervised hierarchical clustering was performed to confirm whether the selected classes would indeed harbor distinct gene expression signatures for the 2,096 whole-genome gene expression profiles. Strong differences were observed in the respective signatures for classes C1 to C18 (Fig 1).

Next, a method developed by Tibshirani and Hastie,¹⁸ established for high-dimensional classification of cancer microarray data, was applied. This method not only produces a classifier, but also gives output graphs, so-called margin trees, that indicate the relatedness of different disease entities.¹⁸ A hierarchical data tree applied to our data set of 2,096 samples is shown in Figure 2, where two major branches can be observed, one that contains mainly the B-lineage ALL categories and a second larger branch that contains the myeloid and chronic leukemias. MDS samples and nonleukemia specimens were also located in this larger branch. The binary decision tree and the hierarchical relationship among the classes can be interpreted in a top-down manner and demonstrated a meaningful organization of the 16 leukemia classes and MDS on the basis of their respective gene expression signatures.

The series of 1,292 acute leukemia samples represented in the stage I cohort were further evaluated for gene signatures that would serve as a so-called virtual immunophenotype. Fourteen distinct types of acute leukemias (C1 to C14) are displayed in a heat map of the genes encoding 21 differentiation antigens routinely used for flow cytometry (Fig 3A). For each of the three major lineages involved in leukemia (B

Fig 2. Exploratory margin tree analysis. Margin tree classification is a supervised multiclass support vector machine classification method.¹⁸ The margin tree program was applied to the stage I data set of 2,096 samples, characterized by their 18 class subtype labels (C1 to C18), and was based on 54,630 probe sets. B-ALL, B-cell acute lymphoblastic leukemia; *MLL*, myeloid/lymphoid or mixed-lineage leukemia; pre, precursor; c-ALL, childhood acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; kt., karyotype; abn., abnormality; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome.

cells, T cells, and myeloid cells), distinct clusters were observed based on the gene expression signature of the corresponding antigens. Subtype-specific patterns were identifiable, for example, the low expression of HLA-DR α and γ antigens in AML with t(15;17) (C10). Such subtype-specific patterns became even more obvious when virtual immunophenotype data were represented as a series of individual box plots for each of the 14 classes of acute leukemias (Fig 3B).

Algorithm Training for Classification Analysis

The classification performance of retrospective samples of stage I was investigated next by developing a prediction algorithm based on linear discriminant classification. To estimate the performance of the classifiers, three independent 30-fold cross-validations were used. For every possible pair of comparisons between the 18 distinct classes, the top 100 probe sets with the largest absolute values of *t* statistics were

Fig 3. Virtual immunophenotypes for 1,292 acute leukemia specimens from stage I of the Microarray Innovations in Leukemia study. (A) Microarray gene expression signal intensities of 21 differentiation antigens currently tested in flow cytometry for the diagnosis of leukemia represented by 32 probe sets. (B) Gene expression intensities for *CD3G*, *CD19*, *CD33*, and *HLA-DRA*. Each dot represents the data from a single microarray profile. B-ALL, B-cell acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; AML, acute myeloid leukemia.

Fig 3. continued.

selected. The union of all selected probe sets was then used for subsequent classification of all class pairs.

When all 2,096 samples from stage I were included, the classification analysis of their whole-genome gene expression profiles demonstrated that overall, in 92.2% of samples, the gene expression classification was concordant with the initial gold-standard diagnosis (99.6% specimens with a unique call). This means that a small number of samples received indeterminable calls as a result of ties of majority votes of the classifier (Table 2). In seven of the 18 classes, the concordance was $\geq 94.6\%$. As detailed in the confusion matrix, lower sensitivities in predicting leukemia types were observed, in particular, for classes C1, C7, C8, C12, and C14. This can largely be explained by the biologic heterogeneity within the class and the lack of standardized gold-standard definitions. However, it is notable that all analyzed classes showed specificities greater than 98.1% and that, overall, all 18 analyzed classes could be predicted with a median sensitivity of 92.1% and a median specificity of 99.7%.

Classification Algorithm Testing on an Independent Patient Cohort

After completion of stage I, the participating laboratories prospectively collected 1,191 samples as an independent validation cohort. Similar to stage I, only samples were included where a full gold standard diagnostic work-up had been completed by the laboratories so that each specimen would be grouped into one of the 18 study classes before microarray analysis. Experiments were performed using

a standardized procedure and a customized chip, the AmpliChip Leukemia microarray. Of the 1,191 stage II gene expression profiles, 1,152 (96.7%) passed the quality criteria and were further processed for microarray classification. When using a prediction model, trained on the whole-genome gene expression profiles from stage I, the overall accuracy for all 18 classes of this independent test cohort using the custom chip was 88.1% (overall call rate, 99.6%). Similar to the stage I data set, miscalls were predominantly observed for the interface of C7/C8 in ALL and in the MDS-AML continuum. The predicted accuracies for CLL, chronic myelogenous leukemia, and MDS in stage II were 98.7%, 93.0%, and 81.5%, respectively.

When focused on an acute leukemia-type diagnostic algorithm, the overall prediction accuracy for all called samples markedly increased to 91.5% (overall call rate, 98.1%). As shown by the confusion matrix in Table 3, 100% correct predictions were observed for five leukemia types (C1, C2, C6, C9, and C11), each of which represented leukemias with discrete disease-defining fusion genes. Lower accuracies were observed for the interface of C7/C8 in ALL, as well as for more intrinsically heterogeneous subtypes such as C12 and C14 in AML. Nonetheless, eight of the 14 represented acute leukemia types were concordant with the gold standard in $\geq 95.0\%$ of the analyses. When summarized over all acute leukemia subtypes, this focused classification scheme resulted in a 95.6% median sensitivity and a 99.8% median specificity for the eight ALL and six AML classes included in the classifier (C1 to C14, $n = 693$). This result reinforces the strength of microarray technology, which offers high positive

Table 2. Whole-Genome Classification Confusion Matrix

GS/Call	Class Prediction																		Average No. of IDC As a Result of Ties of Majority Votes	Total No. of Specimens in Every Class	CR	Sensitivity for Called Specimens	Specificity for Called Specimens
	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12	C13	C14	C15	C16	C17	C18					
C1/GS	9.3*	—	—	—	—	—	—	0.7†	—	—	—	—	0.3†	—	—	—	0.3†	1†	1.3	13	0.897	0.800	0.999
C2/GS	—	70*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	70	1.000	1.000	0.998
C3/GS	—	—	114.3*	—	—	—	0.3†	7.3†	—	—	—	—	—	—	—	—	—	—	0	122	1.000	0.937	0.997
C4/GS	—	—	—	166.3*	—	—	—	1.7†	—	—	—	—	4†	—	—	—	0.3†	0.7†	1	174	0.994	0.961	0.997
C5/GS	—	—	—	—	53.7*	—	—	4.3†	—	—	—	—	—	—	—	—	—	—	0	58	1.000	0.925	0.997
C6/GS	—	2†	—	—	—	33*	—	1†	—	—	—	—	—	—	—	—	—	—	0	36	1.000	0.917	1.000
C7/GS	—	—	—	—	—	—	30.3*	9.7†	—	—	—	—	—	—	—	—	—	—	0	40	1.000	0.758	0.995
C8/GS	1†	3†	5.3†	1†	6†	—	10.7†	205.3*	—	—	—	—	0.3†	1†	1†	—	1.7†	—	0.7	237	0.997	0.869	0.985
C9/GS	—	—	—	—	—	—	—	—	40*	—	—	—	—	—	—	—	—	—	0	40	1.000	1.000	1.000
C10/GS	—	—	—	—	—	—	—	—	—	35*	—	—	1†	—	—	—	1†	—	0	37	1.000	0.946	1.000
C11/GS	—	—	—	—	—	—	—	—	—	—	28*	—	—	—	—	—	—	—	0	28	1.000	1.000	1.000
C12/GS	—	—	—	1†	—	—	—	—	—	—	—	32*	5†	—	—	—	—	—	0	38	1.000	0.842	0.999
C13/GS	1†	—	—	4.3†	—	—	—	3†	—	1†	—	2†	311.3*	9.7†	1.3†	0.7†	15.3†	—	1.3	351	0.996	0.890	0.982
C14/GS	—	—	—	—	—	—	—	—	—	—	—	—	9.3†	35.7*	—	—	2.7†	—	0.3	48	0.993	0.748	0.995
C15/GS	—	—	—	—	—	—	—	—	—	—	—	—	0.7†	—	446*	—	0.3†	—	1	448	0.998	0.998	0.998
C16/GS	—	—	1†	—	—	—	—	—	—	—	—	—	—	—	—	72*	0.3†	2.7†	0	76	1.000	0.947	0.999
C17/GS	—	—	—	—	—	—	—	—	—	—	—	—	11†	—	—	—	184.3*	7.7†	3	206	0.985	0.908	0.981
C18/GS	—	—	—	—	—	—	—	1†	—	—	—	—	—	—	1†	1†	14†	57*	0	74	1.000	0.770	0.994

NOTE. Classification prediction results for 2,096 samples from stage I as analyzed by three 30-fold cross validations. Gold standard classes are given in rows C1/GS to C18/GS; the columns C1 to C18 list the average numbers of calls, rounded with up to 1 decimal place, for every class in three independent runs of cross-validations. This model uses trimmed mean of differences between perfect match and mismatch intensities with quantile normalization (DQN) signal intensities obtained from HG-U133 Plus 2.0 microarrays.

Abbreviations: IDC, indeterminable calls; CR, call rate [(No. of specimens-IDC)/No. of specimens]; GS, gold standard.

*Values indicate correct prediction results.

†Values represent misclassifications for each class.

prediction accuracy based on a standardized, robust, and objective molecular assay.

During the process of clarifying discrepant results (ie, comparing microarray classifier predictions against the gold-standard diagnoses

submitted to the study database), in 51 (7.4%) of 693 acute leukemia samples, discrepancies could be resolved. A first category of 22 (43%) of 51 discrepant samples were explained either because of erroneous entries into case report forms or wrong sample labels (n = 13, 25%) or

Table 3. Independent Testing Set of Acute Leukemias

GS/Call	Class Prediction														Average No. of IDC As a Result of Ties of Majority Votes	Total No. of Specimens in Every Class	CR	Sensitivity for Called Specimens	Specificity for Called Specimens	
	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12	C13	C14						
C1/GS	4*	—	—	—	—	—	—	—	—	—	—	—	—	—	1	5	0.800	1.000	0.999	
C2/GS	—	23*	—	—	—	—	—	—	—	—	—	—	—	—	0	23	1.000	1.000	0.998	
C3/GS	—	—	53*	—	—	—	—	8†	—	—	—	—	1†	—	0	62	1.000	0.855	0.995	
C4/GS	—	—	—	75*	1†	—	—	1†	—	—	—	—	1†	—	1	79	0.987	0.962	0.992	
C5/GS	—	—	—	—	59*	—	—	5†	—	—	—	—	—	—	0	64	1.000	0.922	0.995	
C6/GS	—	—	—	—	—	10*	—	—	—	—	—	—	—	—	0	10	1.000	1.000	0.997	
C7/GS	—	—	—	—	—	—	22*	12†	—	—	—	—	—	—	1	35	0.971	0.647	0.989	
C8/GS	1†	1†	2†	—	2†	2†	7†	141*	—	—	—	—	—	—	2	158	0.987	0.904	0.950	
C9/GS	—	—	—	—	—	—	—	—	16*	—	—	—	—	—	0	16	1.000	1.000	1.000	
C10/GS	—	—	—	—	—	—	—	—	—	19*	—	—	—	1†	0	20	1.000	0.950	0.998	
C11/GS	—	—	—	—	—	—	—	—	—	—	20*	—	—	—	0	20	1.000	1.000	1.000	
C12/GS	—	—	—	—	1†	—	—	—	—	—	—	15*	1†	—	0	17	1.000	0.882	1.000	
C13/GS	—	—	—	1†	3†	—	—	—	—	1†	—	—	—	148*	1†	6	160	0.963	0.961	0.985
C14/GS	—	—	—	—	1†	—	—	—	—	—	—	—	—	4†	17*	2	24	0.917	0.773	0.998

NOTE. Classification prediction results for 693 prospectively collected acute leukemia samples from stage II. Gold standard classes are given in rows C1/GS to C14/GS; the prediction results are displayed for each sample in columns C1 to C14.

Abbreviations: IDC, indeterminable calls; CR, call rate [(No. of specimens-IDC)/No. of specimens]; GS, gold standard.

*Values indicate correct prediction results.

†Values represent misclassifications for each class.

because the respective diagnoses were revised after central independent expert review of karyotypes using the definition of AML with complex aberrant karyotypes from Schoch et al²³ (n = 9, 18%).

A second category of 29 (57%) of 51 discrepant samples could be interpreted as samples in which the chip-based prediction had outperformed the laboratories' own gold standard diagnostic result (overall, 29 of 693 samples; 4.2%). These samples were split between specimens in which subsequent retesting of leftover material confirmed the predicted acute leukemia subtype as classified by the microarray (n = 14) and specimens in which re-evaluation of initial diagnostic reports including morphology or DNA index values led to the confirmation of the microarray classification result (n = 15). More detailed information on the discrepant results analyses performed on these samples is available online (Appendix Tables A1-A3 and Figures A1-A4, online only).

DISCUSSION

In 2005, the International MILE Study Group was formed around the ELN (Gene Expression Profiling Working Group) in 11 laboratories across three continents. In two stages, the clinical accuracy of gene expression profiles of 16 acute and chronic leukemia subclasses, MDS, and a so-called "none of the target classes" control group was compared with current routine diagnostic work-up in 3,334 patients. Gold standard diagnostic methods were not standardized between centers. Each center integrated the available results from their own laboratory workflow and assigned each sample into one of the 18 MILE study microarray categories.

In stage I of the study, only 2.2% of samples failed the strict quality criteria, leaving 2,096 of 2,143 samples to be used in the training of a robust diagnostic classification algorithm. As demonstrated by various exploratory data analyses, each of the 18 diagnostic categories was characterized by a specific underlying gene expression program. The accuracy of this training cohort was estimated by cross-validation and was 92.2% for the 18 classes (median specificity, 99.7%). In seven of the 18 classes, the concordance was $\geq 94.6\%$. A high prediction precision of 100% was observed, in particular, for the group of acute leukemias with specific chromosomal aberrations [eg, as demonstrated for pro-B-ALL with t(11q23)/*MLL* or the core binding factor leukemias AML with t(8;21) or AML with inv(16)/t(16;16)]. Lower sensitivities were seen in entities with biologic heterogeneity within the class (eg, AML with a complex aberrant karyotype [74.8%] or ALL with a hyperdiploid karyotype [75.8%]). However, it is notable that all analyzed classes showed specificities greater than 98.1% and that, overall, all 18 analyzed classes could be predicted with a median sensitivity of 92.1% and a median specificity of 99.7%. Thus, in terms of sensitivity and specificity, the gene expression results alone compared favorably with the laboratories' own gold-standard classification.

The potential clinical utility of microarray-based diagnostics was then validated in stage II including another 1,152 patients, a cohort that represented an independent and blinded validation set for the classification algorithms developed in stage I. Overall, in stage II, the observed accuracy of the classifier prediction across all 18 classes was 88.1%. The accuracy increased to 91.5% when focused on acute leukemias, representing all 14 distinct classes. In

eight of the 14 represented acute leukemia classes, microarray diagnoses were concordant with the gold standard diagnoses in $\geq 95.0\%$ of the analyses.

To our knowledge, this is thus far the largest gene expression microarray profiling study in hematology and oncology, and it clearly underlines the robust performance of this method and demonstrates the possibility of completely standardized laboratory procedures combined with sophisticated data algorithms. This is in contrast to other, far more subjective methods routinely used for leukemia diagnosis today, such as cytomorphology and metaphase cytogenetics. The next step would now be an objective and unbiased discussion on how to position microarray technology in a routine diagnostic workflow and whether it is suitable to helpfully support or even replace some of the existing gold-standard techniques. For example, an array-based test cannot, in all cases, replace multiparameter flow cytometry or reverse transcriptase polymerase chain reaction–based detection of molecular fusion genes, which is routinely applied to define the starting point for clinically relevant detection of minimal residual disease.^{24,25}

In one possible scenario, one could restrict the microarray technique to the classification of acute leukemias because CLL and chronic myelogenous leukemia are readily diagnosed by standard immunophenotyping, cytogenetics, and molecular tests. An acute leukemia classification microarray may then have utility in patients for whom a conventional cytogenetic analysis is not available, either because of no analyzable mitoses or poor quality of banded chromosomes.^{26,27}

Although our study concept had to define up front the most necessary leukemia entities and not all recurrent cytogenetic subtypes according to the new WHO classification of 2008²⁸ were represented by the actual data set, most subtypes with current clinical relevance are covered. As a further intended use, this microarray technique may also serve to classify leukemia in developing countries that currently lack expertise to perform the current labor-intensive and sophisticated diagnostic approaches.

Finally, the investigators of the MILE study submitted their gene expression database to the public domain (Gene Expression Omnibus Accession No. GSE13204) to foster research elucidating the molecular understanding of leukemias. Future refinements need to include additional signatures for prognostically important subsets of patients with AML with normal cytogenetics.^{12,13,29,30} Such signatures have already been tentatively identified by a number of groups.^{31–37} Microarray analysis can even be applied to investigate expression signatures of other novel markers such as *WT1*,³⁸ detect a specific pattern for *RUNX1*-mutated AML,³⁹ and discover predictive signatures for response to both currently used and novel targeted treatment regimens.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: Torsten Haferlach, MLL Munich Leukemia Laboratory (C); Alexander Kohlmann, MLL Munich Leukemia Laboratory (C); Lothar Wiecek, Roche Molecular Systems (C); Peter R. Papenhausen, Laboratory Corporation of America (C); Wei-min Liu, Roche Molecular Systems (C); P. Mickey Williams, Roche Molecular Systems (C) **Consultant or Advisory Role:** Torsten Haferlach, Hoffmann-La Roche (C) **Stock Ownership:** None **Honoraria:** Torsten Haferlach, Hoffmann-La Roche; Ken I. Mills, Roche Molecular Systems; Robin Foà, Roche Molecular Systems **Research Funding:** Torsten Haferlach, Roche Molecular Systems; Giuseppe Basso, Roche Molecular Systems; Geertruy Te Kronnie, Roche Molecular Systems; Marie-Christine Béné, Roche Molecular Systems; John De Vos, Roche Molecular Systems; Jesus M. Hernández, Roche Molecular Systems; Wolf-Karsten Hofmann, Roche Molecular Systems; Ken I. Mills, Roche Molecular Systems; Amanda Gilkes, Roche Molecular Systems; Sabina Chiaretti, Roche Molecular Systems; Sheila A. Shurtleff, Roche Molecular Systems; Thomas J. Kipps, Roche Molecular Systems; Laura Z. Rassenti, Roche Molecular Systems; Allen E. Yeoh, Roche Molecular Systems; Peter R. Papenhausen, Roche Molecular Systems; Robin Foà, Roche Molecular Systems **Expert Testimony:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Torsten Haferlach, Alexander Kohlmann
Collection and assembly of data: Torsten Haferlach, Lothar Wiecek, Giuseppe Basso, Geertruy Te Kronnie, Marie-Christine Béné, John De Vos, Jesus M. Hernández, Wolf-Karsten Hofmann, Ken I. Mills, Amanda Gilkes, Sabina Chiaretti, Sheila A. Shurtleff, Thomas J. Kipps, Laura Z. Rassenti, Allen E. Yeoh, Peter R. Papenhausen, Robin Foà
Data analysis and interpretation: Torsten Haferlach, Alexander Kohlmann, Wei-min Liu, P. Mickey Williams
Manuscript writing: Torsten Haferlach, Alexander Kohlmann, Wei-min Liu
Final approval of manuscript: Torsten Haferlach, Alexander Kohlmann, Lothar Wiecek, Giuseppe Basso, Geertruy Te Kronnie, Marie-Christine Béné, John De Vos, Jesus M. Hernández, Wolf-Karsten Hofmann, Ken I. Mills, Amanda Gilkes, Sabina Chiaretti, Sheila A. Shurtleff, Thomas J. Kipps, Laura Z. Rassenti, Allen E. Yeoh, Peter R. Papenhausen, Wei-min Liu, P. Mickey Williams, Robin Foà

REFERENCES

- Wouters BJ, Lowenberg B, Delwel R: A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects. *Blood* 113:291-298, 2009
- Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. *Nat Genet* 30:41-47, 2002
- Campo Dell'Orto M, Zangrando A, Trentin L, et al: New data on robustness of gene expression signatures in leukemia: Comparison of three distinct total RNA preparation procedures. *BMC Genomics* 8:188, 2007
- Chiaretti S, Li X, Gentleman R, et al: Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. *Blood* 103:2771-2778, 2004
- Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. *Science* 286:531-537, 1999
- Kohlmann A, Schoch C, Schnittger S, et al: Molecular characterization of acute leukemias by use of microarray technology. *Genes Chromosomes Cancer* 37:396-405, 2003
- Kohlmann A, Schoch C, Schnittger S, et al: Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. *Leukemia* 18:63-71, 2004
- Ross ME, Zhou X, Song G, et al: Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. *Blood* 102:2951-2959, 2003
- Ross ME, Mahfouz R, Onciu M, et al: Gene expression profiling of pediatric acute myelogenous leukemia. *Blood* 104:3679-3687, 2004
- Yeoh EJ, Ross ME, Shurtleff SA, et al: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell* 1:133-143, 2002
- Schoch C, Kohlmann A, Schnittger S, et al: Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. *Proc Natl Acad Sci U S A* 99:10008-10013, 2002
- Valk PJ, Verhaak RG, Beijnen MA, et al: Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med* 350:1617-1628, 2004
- Bullinger L, Dohner K, Bair E, et al: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. *N Engl J Med* 350:1605-1616, 2004
- Haferlach T, Kohlmann A, Schnittger S, et al: Global approach to the diagnosis of leukemia using gene expression profiling. *Blood* 106:1189-1198, 2005
- Kohlmann A, Kipps TJ, Rassenti LZ, et al: An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: The Microarray Innovations in LEukemia study prephase. *Br J Haematol* 142:802-807, 2008
- Liu WM, Li R, Sun JZ, et al: PQN and DQN: Algorithms for expression microarrays. *J Theor Biol* 243:273-278, 2006
- Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 95:14863-14868, 1998
- Tibshirani R, Hastie T: Margin trees for high-dimensional classification. *J Mach Learn Res* 8:637-652, 2007
- Barrett T, Suzek TO, Troup DB, et al: NCBI GEO: Mining millions of expression profiles—Database and tools. *Nucleic Acids Res* 33:D562-D566, 2005
- Kohlmann A, Haschke-Becher E, Wimmer B, et al: Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: The DACH study. *Clin Chem* 54:1705-1715, 2008
- Chang C-C, Lin C-J: LIBSVM: A library for support vector machines. <http://www.csie.ntu.edu.tw/~cjlin/libsvm>
- Vapnik VN: *The Nature of Statistical Learning Theory*. New York, NY, Springer-Verlag, 1995
- Schoch C, Kern W, Kohlmann A, et al: Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. *Genes Chromosomes Cancer* 43:227-238, 2005
- Kern W, Haferlach C, Haferlach T, et al: Monitoring of minimal residual disease in acute myeloid leukemia. *Cancer* 112:4-16, 2008
- Paganin M, Zecca M, Fabbri G, et al: Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. *Leukemia* 22:2193-2200, 2008
- Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 100:4325-4336, 2002
- Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood* 98:1312-1320, 2001
- Swerdlow SH, Campo E, Harris NL, et al: *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues* (ed 4). Lyon, France, International Agency for Research on Cancer, 2008
- Metzeler KH, Hummel M, Bloomfield CD, et al: An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. *Blood* 112:4193-4201, 2008
- Radmacher MD, Marcucci G, Ruppert AS, et al: Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: A Cancer and Leukemia Group B study. *Blood* 108:1677-1683, 2006
- Alcalay M, Tiacci E, Bergomas R, et al: Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. *Blood* 106:899-902, 2005
- Bullinger L, Dohner K, Kranz R, et al: An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. *Blood* 111:4490-4495, 2008
- Kohlmann A, Bullinger L, Thiede C, et al: Gene expression profiling in AML with normal karyotype: A multicenter study investigating molecular markers in 252 cases. *Blood* 112:751, 2008 (abstr)

34. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. *J Clin Oncol* 26:5078-5087, 2008

35. Verhaak RG, Goudswaard CS, van PW, et al: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic

significance. *Blood* 106:3747-3754, 2005

36. Whitman SP, Ruppert AS, Radmacher MD, et al: FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. *Blood* 111:1552-1559, 2008

37. Wouters BJ, Jorda MA, Keeshan K, et al: Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. *Blood* 110:3706-3714, 2007

38. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. *J Clin Oncol* 26:4595-4602, 2008

39. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. *Blood* 104:1474-1481, 2004

***Journal of Clinical Oncology* — The ideal place to publish your research**

- Impact Factor of 17.157: *JCO*'s published articles were cited 97,639 times and accounted for fully 9.7% of all oncology journal citations in 2008.
- Maximum Exposure: More than 25,000 of the world's leading oncology professionals receive *JCO* and more than 180,000 unique visitors per month visit jco.org.
- Outstanding Reputation: With an acceptance rate of just 20%, *JCO* publishes only the very best articles in the field.
- International Coverage: *JCO* is available globally in 28 countries and in 15 international editions.
- Rapid Turnaround: *JCO* averages just 9 weeks from final manuscript acceptance to online publication.
- No Exclusivity Clause: *JCO* authors may reproduce or reuse their own material published in *JCO* for educational purposes at no charge.
- No Submission Charges: *JCO* has no submission, color, or page charges.

To submit a manuscript, visit submit.jco.org.

American Society of Clinical Oncology